title: Combined effects of lactoferrin and lysozyme on Streptococcus pneumoniae killing.
abstract: Streptococcus pneumoniae is a common colonizer of the human nasopharynx, which can occasionally spread to sterile sites, causing diseases such as otitis media, sinusitis, pneumonia, meningitis and bacteremia. Human apolactoferrin (ALF) and lysozyme (LZ) are two important components of the mucosal innate immune system, exhibiting lytic effects against a wide range of microorganisms. Since they are found in similar niches of the host, it has been proposed that ALF and LZ could act synergistically in controlling bacterial spread throughout the mucosa. The combination of ALF and LZ has been shown to enhance killing of different pathogens in vitro, with ALF facilitating the latter action of LZ. The aim of the present work was to investigate the combined effects of ALF and LZ on S pneumoniae. Concomitant addition of ALF and LZ had a synergistic killing effect on one of the pneumococci tested. Furthermore, the combination of ALF and ALZ was more bactericidal than lysozyme alone in all pneumococcal strains. Pneumococcal surface protein A (PspA), an important vaccine candidate, partially protects pneumococci from ALF mediated killing, while antibodies against one PspA enhance killing of the homologous strain by ALF. However, the serological variability of this molecule could limit the effect of anti-PspA antibodies on different pneumococci. Therefore, we investigated the ability of anti-PspA antibodies to increase ALF-mediated killing of strains that express different PspAs, and found that antisera to the N-terminal region of PspA were able to increase pneumococcal lysis by ALF, independently of the sequence similarities between the molecule expressed on the bacterial surface and that used to produce the antibodies. LF binding to the pneumococcal surface was confirmed by flow cytometry, and found to be inhibited in presence of anti-PspA antibodies. On a whole, the results suggest a contribution of ALF and LZ to pneumococcal clearance, and confirm PspA's ability to interact with ALF.
authors: Laboratório de Biologia Molecular e Farmacologia, Universidade São Francisco, Bragança Paulista, Brazil.
authors: G O
authors: GO
authors: André
authors: Laboratório de Biologia Molecular e Farmacologia, Universidade São Francisco, Bragança Paulista, Brazil.
authors: W R
authors: WR
authors: Politano
authors: Division of Epidemiology, University of Texas Health Science Center at Houston, USA.
authors: S
authors: S
authors: Mirza
authors: Programa de Pós-Graduação Interunidades em Biotecnologia-USP-IPT-IB, São Paulo, Brazil; Centro de Biotecnologia, Instituto Butantan, São Paulo, Brazil.
authors: T R
authors: TR
authors: Converso
authors: Laboratório de Biologia Molecular e Farmacologia, Universidade São Francisco, Bragança Paulista, Brazil.
authors: L F C
authors: LF
authors: Ferraz
authors: Centro de Biotecnologia, Instituto Butantan, São Paulo, Brazil.
authors: L C C
authors: LC
authors: Leite
authors: Laboratório de Biologia Molecular e Farmacologia, Universidade São Francisco, Bragança Paulista, Brazil. Electronic address: michelle.bertoncini@saofrancisco.edu.br.
authors: M
authors: M
authors: Darrieux
mesh_terms: D000900:Anti-Bacterial Agents / Q000378:metabolism*; D001426:Bacterial Proteins / Q000378:metabolism; D004357:Drug Synergism; D006801:Humans; D007781:Lactoferrin / Q000378:metabolism*; D050296:Microbial Viability / Q000187:drug effects*; D009113:Muramidase / Q000378:metabolism*; D011485:Protein Binding; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000502:physiology*
chemical_list: D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; C051592:pneumococcal surface protein A; D009113:Muramidase; D007781:Lactoferrin
keywords: Lactoferrin; Lysozyme; PspA; Streptococcus pneumoniae